Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Announces Results from ACP-104 Phase IIb Schizophrenia Trial
July 11th, 2008
ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD) announced results from its Phase IIb trial with ACP-104 for the treatment of schizophrenia. The study did not meet its primary endpoint of antipsychotic efficacy or any of the secondary endpoints. Neither dose of ACP-104 demonstrated improved efficacy as compared to placebo. The most common adverse events in the treatment arms relative to placebo were increased salivation, tachycardia, and dyspepsia, which were noted to be dose-related. There was no clinically significant decrease in neutrophil counts in the study drug arms. "We clearly are disappointed in the results of this study," said Uli Hacksell, Ph.D., Chief Executive...
Source: Health Business Week (2008-07-11)
|
